Article Versions Notes

Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, et al. The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function. Cancers. 2022; 14(19):4873. https://doi.org/10.3390/cancers14194873

Iwamoto, Hideki, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Joji Tani, Teiji Kuzuya, Kazuhiro Kasai, Youhei Kooka, Atsushi Hiraoka, Rie Sugimoto, and et al. 2022. "The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function" Cancers 14, no. 19: 4873. https://doi.org/10.3390/cancers14194873

Iwamoto, H., Niizeki, T., Nagamatsu, H., Ueshima, K., Tani, J., Kuzuya, T., Kasai, K., Kooka, Y., Hiraoka, A., Sugimoto, R., Yonezawa, T., Tanaka, S., Deguchi, A., Shimose, S., Shirono, T., Sakai, M., Suzuki, H., Moriyama, E., Koga, H., ... Kurume Liver Cancer Study Group of Japan. (2022). The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function. Cancers, 14(19), 4873. https://doi.org/10.3390/cancers14194873